Foreign drug makers must overcome challenges from Korean competitors

Despite the brisk EDI (electronic data interchange) claim results for the first half of this year, foreign players like Pfizer are expected to face an uphill battle in Korea due to intensifying competition from domestic markers, industry sources said recently.

Pfizer Korea's Norvasc (amlodipine besylate) ruled the country's ethical market with 68.2 billion won in the first-half EDI c...